Safe Stop-QoL: Quality of life in patients with advanced melanoma after early discontinuation of nivolumab or pembrolizumab
Checkpoint inhibitors are a type of immunotherapy which is frequently used in cancer. They act by interacting with the patient’s own immune system to combat cancer. This therapy has been very successful in patients with metastatic melanoma, with good responses within 3 months. This project will determine whether the duration of checkpoint inhibitor therapy can be reduced without affecting therapy safety. Additionally, the researchers will investigate how this may affect the quality of life in patients with metastatic melanoma.
The researchers expect improved quality of life in patients who can discontinue checkpoint inhibitor immunotherapy earlier. This may lead to adjustments to treatment guidelines, preventing overtreatment.
More detailed information
Role Erasmus MC:
KWF Kankerbestrijding /
Young Investigator Grant